FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to inhibitor peptides of α-synuclein; it can be used in medicine for inhibiting α-synuclein aggregation. Inhibitor peptide up to 30 amino acids long is proposed, containing GAVVWGVTAVKK or RAVVTGVTAVAE. At least one of amino acids in inhibitor peptide is not found in nature amino acid selected from D-amino acid or amino acid containing a fragment of N-methyl group. Inhibitor peptide also contains a heterologous peptide tag to increase its solubility, relieve its monitoring and/or peptide entry to a mammalian cell.
EFFECT: invention provides for inhibiting the formation, fibril priming, and distribution of alpha-synuclein aggregates.
4 cl, 7 dwg, 4 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| EGFL6-SPECIFIC MONOCLONAL ANTIBODIES AND THEIR APPLICATION METHODS | 2017 |
|
RU2779902C2 |
| CHIMERIC HUMAN MESOTHELIOGEN ANTIGEN RECEPTORS AND USE THEREOF | 2014 |
|
RU2714902C2 |
| COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
| COMPOSITIONS AND METHODS OF GENE EDITING | 2019 |
|
RU2804665C2 |
| GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| TREATING CANCER USING A CHIMERIC ANTIGENIC CLL-1 RECEPTOR | 2015 |
|
RU2741120C2 |
